Beth Faiman, PhD, CNP
Articles
Clinical Scenario: AE Management for Bispecific Therapy in R/R MM
Following the review of a case of a patient with relapsed/refractory multiple myeloma, the panel provides expert perspectives on adverse event management practices.
Adverse Event Management Strategies in GPRC5D Therapy
Experts on multiple myeloma address the intricacies of adverse event management practices, focusing on taste changes and associated weight loss.
Clinical Scenario: AE Management in a Patient with R/R MM on GPRC5D Therapy
Samantha Shenoy, NP, MSN, presents the case of a patient with multiple myeloma and the panel discusses adverse event management practices.
Insights on REMS Programs and Strategies for Effective Patient Care
The panel provides an overview of REMS programs for bispecific therapies in multiple myeloma and discusses how institutions can educate healthcare professionals outside of oncology.
Management and Supportive Care for CRS and ICANS in GPRC5D Therapy
Experts on multiple myeloma discuss prophylactic supportive measures to prevent CRS and ICANS in patients who receive GPRC5D therapy.
Clinical Experience in Managing AEs in GPRC5D Therapy
Mary Steinbach, APRN, shares her experience in managing dysgeusia and nail- and skin-related toxicities seen in patients with multiple myeloma who receive talquetamab.
Clinical Perspective on AE Tolerance
Focusing on patients with multiple myeloma who receive GPRC5D-targeted therapy, Beth Faiman, CNP, PhD, discusses how long-term treatment impacts patients’ tolerance to adverse events.
Administration and Dosing Management
Experts on multiple myeloma offer clinical insights on preparing patients who are going to receive GPRC5D therapy, highlighting step-up and treatment dosing for talquetamab.
Overview of Long-term Follow-up from MonumenTAL-1
Focusing on the MonumenTAL-1 study, Mary Steinbach, APRN, provides clinical insights on nail, skin, and oral toxicities associated with talquetamab.
GPRC5D Therapy: Unique Challenges in Adverse Event Management
Lisa Hwa, APRN, DNP, CNP, FAPO, describes the unique challenges in managing adverse events associated with GPRC5D therapy compared with other bispecifics.
Adverse Event Management with BCMA Therapy
Ellen Marin, PA-C, provides an overview of adverse effects associated with BCMA-directed bispecific therapy in multiple myeloma.
Long-Term Follow-up Overview: MajesTEC-1 and MagnetisMM-3 Recent Data
A panel of experts on multiple myeloma discuss long-term follow-up data from the MajesTEC-1 and MagnetisMM-3 clinical trials.
Unmet Needs and Future Perspectives for CAR T-Cell Therapy in R/R MM
The panel concludes by offering key takeaways on the treatment of patients with relapsed/refractory multiple myeloma who receive CAR T-cell therapy.
Managing Cytopenias and HLH/MAS Following CAR T-Cell Therapy
Continuing the discussion on supportive care strategies, the panel discusses the management of cytopenias and HLH/MAS following CAR T-cell therapy.
Supportive Care Strategies for CAR T-Cell Therapy Recipients
Experts on multiple myeloma provide clinical insights on supportive care strategies for patients experiencing infections or secondary malignancies following CAR T-cell therapy.
The Importance of Multidisciplinary Collaboration in CRS Management
Focusing on supportive care practices, the panel discusses the critical role of effective multidisciplinary team collaboration and communication in optimizing the management of CRS and ICANS in patients receiving CAR T-cell therapy.
Clinical Practices for Treating ICANS Following CAR T-Cell Therapy
The panel provides comprehensive insights on the treatment of ICANS following CAR T-cell therapy, highlighting the role of imaging, clinical trial data, and clinical pearls for community practices.
Patient Profile 2: Managing ICANS Following CAR T-Cell Therapy
Donna Catamero, ANP-BC, OCN, CCRC, presents the case of a 77-year-old patient who experienced ICANS following CAR T-cell therapy and describes the role of the ICE score.
Strategies to Manage or Mitigate CRS
Experts on multiple myeloma provide clinical insights on strategies to manage or mitigate CRS, highlighting premedications, the role of bridging therapy, and potential treatment strategies.
Patient Profile 1: Managing CRS Following CAR T-Cell Therapy
Beth Faiman, CNP, PhD, presents the case of a 76-year-old woman with multiple myeloma who experienced cytokine release syndrome (CRS) following CAR T-cell therapy.
Navigating CAR T-Cell Therapy in Multiple Myeloma: A Collaborative, Patient-Centered Approach
Experts on multiple myeloma discuss how they educate and prepare patients who are going to receive CAR T-cell therapy and provide clinical insights on transitioning patients to community practices following treatment.
Unique Challenges in Managing Adverse Events Associated with CAR T-Cell Therapy
A panel of experts on multiple myeloma give an overview of unique challenges in managing adverse effects associated with CAR T-cell therapy as compared with other cancer therapies.
Managing Infections and Other Toxicities Associated with Bispecifics in MM
June 21st 2023Jeremy Larsen, MD, discusses the management of infections, neurotoxicity, and other side effects associated with bispecifics in patients with R/R MM, including the need for prophylactic antimicrobials and monitoring of immunoglobulin levels.
